BIOTECH 2007 Life Sciences

Summary

Please note: Price includes shipping charges by courier

Annual Biotechnology Industry Report written by G. S Burrill.

Overview

Biotech is undergoing a global transformation before our very eyes and a biotech company of today becomes global from the first day of its formation regardless of where it is located. The global economy is in the midst of radical transformation with far reaching and fundamental changes in technology, production and trading patterns. Rapid technological change continues to impact on how individuals, business and communities interact with each other and with governments.

Global security is being reshaped as the international community responds to the ongoing threat of international terrorism, conflict and the challenges of ending world poverty. The pressures that economic and population growth are placing on the earth's natural resources and climate are increasingly apparent, presenting an urgent need for international cooperation. This transformation will present both challenges and opportunities for the biotech industry. Individuals, businesses and communities all need to be ready to respond to the changing global environment.

G. Steven Burrill's annual book on the "State of the Industry" has been an integral part of the biotech industry's view of itself.

The 21st Edition of BIOTECH 2007 will be focusing on the emergence of biotechnology as a global industry. This not-to-be-missed publication provides an overview of the latest developments and trends in biotech around the world along with detailed analysis on the progress and prospects for each nation reviewed.

In BIOTECH 2007 Life Sciences: A Global Transformation you will find:

• Special features on emerging players such as China, India, Japan, Singapore and Europe
• Interviews with biotech leaders
• 2006 Industry Financials, including 12 months of company financial data and market caps for the US, Europe, Canada and Asia
• An analysis of key activities taking place in various industry sectors including: healthcare, diagnostics, preventative medicine, agbio and industrial biotechnology
• Industry highlights including: new product approvals, advances in technology, scientific activity, as well as a thorough analysis of the venture capital environment and capital markets
• 600 pages of analysis, data and graphs

The book has industry financial data on 360 public biotech companies and includes the following highlights:

• Number of public and private biotech companies by country
• Fastest growing companies by revenue, R&D spending
• Analysis of M&A, partnership deals by phase, by indication, by technology
• Winners and losers in the drug approval stakes
• Number of biotech drugs in the pipeline, by indication, by phase
• Venture capital deals -- by round, by indication, by technology, and by phase
• IPOs -- who got out, who is still on the runway in the US and the rest of the world
• Public company financing -- follow-ons, PIPEs, and Debt

Contents

• 1. Executive Overview
• 2. Technology
• 3. Healthcare
• 4. Diagnostics
• 5. Preventative Medicine
• 6. Agbio
• 7. Industrial and Marine Biology
• 8. Regulatory
• 9. International
• 10. M&A/Partnering
• 11. Finance and Capital Markets
• 12. About Burrill & Company